PT - JOURNAL ARTICLE AU - Almulla, Abbas F. AU - Supasitthumrong, Thitiporn AU - Amrapala, Arisara AU - Tunvirachaisakul, Chavit AU - Abdul Jaleel, Al-Karrar Kais AU - Oxenkrug, Gregory AU - Al-Hakeim, Hussein K. AU - Maes, Michael TI - The tryptophan catabolite or kynurenine pathway in Alzheimer’s disease: a systematic review and meta-analysis AID - 10.1101/2022.03.18.22272608 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.18.22272608 4099 - http://medrxiv.org/content/early/2022/03/21/2022.03.18.22272608.short 4100 - http://medrxiv.org/content/early/2022/03/21/2022.03.18.22272608.full AB - Background Alzheimer’s disease (AD), characterized by gradual brain dysfunction and memory loss, is one of the major elderly health issues worldwide. Neuroinflammation and increased oxidative stress contribute to the pathophysiology of AD, thereby presumably inducing tryptophan (TRP) degradation through the TRP catabolite (TRYCAT) pathway.Objectives To delineate the activity of the TRYCAT pathway along with levels of TRP and tryptophan catabolites (TRYCATs) in AD patients.Methods We employed PubMed, Google Scholar, Web of Science, and SciFinder to obtain the relevant articles through a search process lasting the entire February 2022. We found 19 eligible articles which involved 738 patients and 665 healthy controls.Results Our result revealed a significant difference (p = 0.008) in the kynurenine (KYN)/TRP ratio (standardized mean difference, SMD = 0.216, 95% confidence interval, CI: 0.057; 0.376), and a significant decrease in TRP in AD patients (SMD = -0.520, 95% CI: -0.738; -0.302, p < 0.0001). Moreover, we also found a significant increase in the central nervous system (CNS, brain and cerebrospinal fluid, CSF) kynurenic acid (KA)/KYN ratio but not in peripheral blood, as well as a significant decrease in plasma KA and xanthurenic acid (XA) in the CNS and blood.Conclusions AD is characterized by TRP depletion but not by an overactivity of the TRYCAT pathway. IDO-induced production of neurotoxic TRYCATs is not a key factor in the pathophysiology of AD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the C2F program, Chulalongkorn University, Thailand.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOn a reasonable request and after the authors have fully used the dataset, the employed dataset (excel file) developed for this meta-analysis will be accessible from MM.